• Caris Life Sciences said the Caris Precision Oncology Alliance and collaborators will present six oncology studies at the 2026 AACR Annual Meeting in San Diego, scheduled for April 17-22, 2026.
• The studies used Caris’ multimodal database integrating Whole Exome Sequencing $(WES)$, Whole Transcriptome Sequencing $(WTS)$, immunohistochemistry $(IHC)$ and real world clinical data across breast, prostate, lung and colorectal cancers.
• Poster sessions are slated for April 19-21, 2026, including topics such as tumor-cell MHC class II in triple-negative breast cancer and TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC.
• Additional presentations will cover AR copy number amplification and AR/KLK3 expression patterns in metastatic castration resistance prostate cancer (mCRPC) and KRAS mutation codons and microsatellite instability in colorectal carcinoma.
• James Hamrick, Chairman of the Caris POA, said the work combines deep genomic profiling with real world clinical evidence to inform treatment decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA18460) on March 25, 2026, and is solely responsible for the information contained therein.